Gilead Sciences, Inc.
GILDInvestors are reacting to coverage highlighting four potential 2026 drug launches and solid Q1 results (revenue +4% YoY, EPS +54.8%), prompting reassessment of Gilead's near-term growth prospects.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $28.75B | $27.12B | $27.28B | $27.30B | $24.69B | $22.45B | $22.13B | $26.11B |
| Cost of Revenue | $6.25B | $6.50B | $5.66B | $6.60B | $4.57B | $4.67B | $4.85B | $4.37B |
| Gross Profit | $22.50B | $20.62B | $21.62B | $20.70B | $20.12B | $17.77B | $17.27B | $21.74B |
| Gross Margin | 78.26% | 76.04% | 79.26% | 75.82% | 81.48% | 79.18% | 78.07% | 83.26% |
| Operating Expenses | $20.84B | $13.01B | $14.29B | $10.79B | $16.05B | $13.49B | $9.07B | $7.61B |
| Operating Income | $1.66B | $7.61B | $7.33B | $9.92B | $4.07B | $4.29B | $8.20B | $14.12B |
| Operating Margin | 5.78% | 28.05% | 26.87% | 36.32% | 16.49% | 19.10% | 37.06% | 54.10% |
| Net Income | $480.00M | $5.67B | $4.59B | $6.22B | $123.00M | $5.39B | $5.46B | $4.63B |
| Net Margin | 1.67% | 20.89% | 16.83% | 22.80% | 0.50% | 23.99% | 24.65% | 17.73% |
| EPS (Basic) | $0.38 | $4.54 | $3.66 | $4.96 | $0.10 | $4.24 | $4.20 | $3.54 |
| EBITDA | $4.43B | $10.50B | $8.85B | $11.33B | $4.13B | $7.56B | $10.30B | $15.93B |
| Stock Option Compensation Expense | $835.00M | $766.00M | $644.00M | $635.00M | $643.00M | $636.00M | $845.00M | $638.00M |
| Price To Earnings Ratio | 239.97 | 17.85 | 23.46 | 14.65 | 595.39 | 15.32 | 14.88 | 20.23 |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | $115.19B | $101.10B | $107.74B | $91.20B | $73.23B | $82.52B | $81.19B | $93.63B |
Company coverage
Latest news
Show 12 more stories
Insider Trading
View AllCompany
About the company
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.